CD44 and neoplasm: The stimuli related to PPARγ activity gave by Rosiglitazone and GW-9662, did not change the profile of tumor stem cells, translated by the absence of significant change in the percentage of this cell population, measured by the balance between CD24−/CD44+ expression.